Clinical Trial Update: A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability update for LPCN 1144 in subjects who completed the LPCN 1144-18-002 trial for Nonalcoholic Steatohepatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• LPCN 1144

Snippet

Sponsor: Lipocine Inc. | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2024-07-17